The deal would include an option for expansion to 160 million doses of the mRNA-based vaccine.
The first participants have been dosed in a Phase I trial of AZD7442, AstraZeneca PLC’s combination of two monoclonal antibodies (mAbs) for the prevention and treatment of COVID-19.
The trial will evaluate the safety, tolerability and pharmacokinetics of the antibody cocktail in up to 48 healthy
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.
Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.
